Behçet's syndrome: response to infliximab after failure of etanercept

Abstract
Sir, Anti‐tumour necrosis factor α (TNF‐α) therapy is being used with considerable success to suppress disease activity in patients with Behçet's syndrome (BS) [1–3]. We report a patient with refractory BS who failed to respond to etanercept but who responded dramatically to infliximab.